Skip to main content
SpringerLink
Log in

Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Encapsulation in polyethylene glycol-coated (pegylated; Stealth®) liposomes alters the pharmacokinetic characteristics, and hence the safety and tolerability profile, of doxorubicin.

Pegylated liposomal doxorubicin administered as a single agent is generally well tolerated. Grade III/IV leucopenia, stomatitis and palmar-plantar erythrodysaesthesia affected 16, 6 and 18% of solid tumour patients, respectively. Other adverse effects included nausea and vomiting and alopecia. Acute hypersensitivity infusion reactions have been reported in up to 9% of patients in some studies. Recently published data from a phase II trial in patients with refractory ovarian cancer showed no alopecia or cardiotoxicity and little nausea and vomiting after pegylated liposomal doxorubicin. Unlike free doxorubicin, pegylated liposomal doxorubicin is not a vesicant.

Preliminary data, not yet confirmed in comparative studies, suggest that the pegylated liposomal formulation may be less cardiotoxic than free doxorubicin. Mucositis, however, appears to be increased. Studies to determine optimal dosing schedules and safety of pegylated liposomal doxorubicin in combination with other agents are ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hortobagyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs 1997; 54Suppl. 4: 1–7

    Article  PubMed  CAS  Google Scholar 

  2. Gabizon AA, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 1997; 54Suppl. 4: 15–21

    Article  PubMed  CAS  Google Scholar 

  3. SEQUUS Pharmaceuticals Inc. Doxil safety report (07 Apr 1997). Menlo Park, California, USA

  4. Dezube BJ. Safety assessment: Doxil® (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi’s sarcoma. Doxil® Clinical Series Vol. 1, No. 2; SEQUUS Pharmaceuticals, Inc., Menlo Park, California, 1996

    Google Scholar 

  5. Muggia FM, Amantea M, Jeffers S, et al. DOXIL (doxorubicin in stealth liposomes): a drug with favorable therapeutic index in the management of refractory epithelial ovarian cancer [abstract no. 31]. Cancer Invest 1996; 14Suppl. 1: 39–41

    Google Scholar 

  6. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13(7): 1777–85

    PubMed  CAS  Google Scholar 

  7. Muggia FM, Hainsworth J, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–993

    PubMed  CAS  Google Scholar 

  8. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi’s sarcoma. Drugs 1997; 53(3): 520–38

    Article  PubMed  CAS  Google Scholar 

  9. Working PK, Dayan AD. Pharmacological-toxicological expert report: Caelyx™ (Stealth® liposomal doxorubicin HCl). Hum Exp Toxicol 1996; 15: 752–85

    Article  Google Scholar 

  10. Lokich JJ, Moore C. Chemotherapy-associated palmar plantar erythrodysesthesia syndrome. Ann Int Med 1984; 101: 798–800

    PubMed  CAS  Google Scholar 

  11. Ranson M, O’Byrne K, Carmichael J, et al. Phase II dose-finding trial of DOX-SL™ (Stealth® liposomal doxorubicin HCl) in the treatment of advanced breast cancer [abstract no. 161]. Proc Am Soc Clin Oncol 1996; 15: 124

    Google Scholar 

  12. Venook AP, Amantea M, Bonnem E, et al. Pegylated liposome-encapsulated doxorubicin (Doxil®) in patients with hepatocellular carcinoma (HCC) [abstract no. 1494]. Proc Am Soc Clin One 1996; 15: 473

    Google Scholar 

  13. Olver IN, Aisner J, Hament A, et al. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988; 6(11): 1732–5

    PubMed  CAS  Google Scholar 

  14. Bertelli G, Gozza A, Forno GB, et al. Topical dimethyl sulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13: 2851–5

    PubMed  CAS  Google Scholar 

  15. Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin [letter]. J Natl Cancer Inst 1995; 87(20): 154–5

    Article  Google Scholar 

  16. Hengge UR, Brockmeyer NH, Rasshofer R, et al. Fatal hepatic failure with liposomal doxorubicin [letter]. Lancet 1993; 341: 383–4

    Article  PubMed  CAS  Google Scholar 

  17. Coker RJ, James ND, Stewart JSW. Hepatic toxicity of liposomal encapsulated doxorubicin [letter]. Lancet 1993; 341: 756

    Article  PubMed  CAS  Google Scholar 

  18. Saltiel E, McGuire W. Doxorubicin (adriamycin) cardiomyopathy: a critical review. West J Med 1983; 139: 332–41

    PubMed  CAS  Google Scholar 

  19. Bielack SS, Erttmann R, Kempf-Bielack B, et al. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 1996; 32A(10): 1652–60

    Article  PubMed  CAS  Google Scholar 

  20. Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin [abstract]. Cancer Res Treat 1996; 37 Suppl.: 77

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arizona Cancer Center, PO Box 245024, 1515 N. Campbell Ave, Tucson, Arizona, 85724-5024, USA

    David S. Alberts & Dava J. Garcia

Authors
  1. David S. Alberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dava J. Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alberts, D.S., Garcia, D.J. Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer. Drugs 54 (Suppl 4), 30–35 (1997). https://doi.org/10.2165/00003495-199700544-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199700544-00007

Keywords

Search

Navigation